https://www.selleckchem.com/products/au-15330.html
43, 95% CI 0.10－2.75, P = 0.03; WMD = 3.09, 95% CI 1.49－4.68, P = 0.0002), as well as after the 10th to 12th treatment (WMD = 1.81, 95% CI 0.31－3.31, P = 0.02) though not after the 5th to 6th (WMD = 1.88, 95% CI －2.10 to 5.86, P = 0.35). LI-ESWT also significantly increased the IIEF scores in the patients with the baseline IIEF ≥12 (WMD = 2.13, 95% CI 0.51－3.75, P = 0.01) but not in those with the baseline IIEF ≤11 (WMD = 1.04, 95% CI －0.96 to 3.03, P = 0.31). No significant adverse events were reported in the 8 RCTs. CONCLUSIONS As a